United Kingdom (UK)
Recombinant monoclonal antibody to CEA. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma T84.66.
UniProt Accession Number of Target Protein: P06731
Alternative Name(s) of Target: Carcinoembryonic antigen; Carcinoembryonic antigen-related cell adhesion molecule 5; CEACAM5; Meconium antigen 100; CD66e
Immunogen: The original antibody was generated by immunizing female BALB/c mice subcutaneously with soluble CEA or with the HC84S cell line.
Specificity: This antibody binds the A3 domain of the human carcinoembryonic antigen.
Application Notes: The binding affinity of the original mouse antibody to carcinoembryonic antigen was determined using a competitive radioimmunoassay (PMID: 6187848). 111In (Indacea) labelled version of this antibody was used to image tumors in patients with colorectal cancer (PMID: 3779658). An engineered antibody fragment (VL-VH-CH3, or "minibody") generated using this antibody having bivalent binding to carcinoembryonic antigen showed high level targeting of xenografts (PMID: 8674062). A radiolabeled chimeric version of this antibody was used to target breast cancer cells expressing high levels of CEA and it was found that chimeric 86.66 resulted in good tumor localization as well as significant tumor growth inhibition. This antibody was also used to detect CEA expression in Human breast carcinoma cell line, MCF 7, using flow cytometry and immunohistochemistry (PMID: 21597719). The characterization of the chimeric version of this antibody generated by transient expression in tobacco leaves was done using ELISA (PMID: 10500141). A phase 1 clinical radioimmunotherapy trial studying 22 patients with metastatic CEA-producing malignancies involving 90Yttrium-labeled chimeric T86.44 revealed that the antibody was well tolerated, with reversible thrombocytopenia and leukopenia being dose limiting (PMID: 11051230). This antibody was used in the immunohistochemical staining of paraffin sections of primary tumours from 252 consecutive patients with breast carcinomas (PMID: 9635845).
Antibody first published in:
Wagener et al. Monoclonal antibodies for carcinoembryonic antigen and related antigens as a model system: determination of affinities and specificities of monoclonal antibodies by using biotin-labeled antibodies and avidin as precipitating agent in a solution phase immunoassay. J Immunol. 1983 May;130(5):2302-7. PMID:6187848
Note on publication:
Describes the use of competitive radioimmunoassay as a method for determination of affinity constants and antigen cross-reactivities of monoclonal antibodies.